Alkermes plc (ALKS)
USD 28.87
(-3.98%)
USD 28.87
(-3.98%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 495.04 Million USD | 606.22% |
| 2022 | 59.77 Million USD | -936.97% |
| 2021 | 176.39 Million USD | 121.94% |
| 2020 | -6.02 Million USD | 51.01% |
| 2019 | -103.04 Million USD | -299.43% |
| 2018 | -10.17 Million USD | 70.53% |
| 2017 | -32.74 Million USD | 37.99% |
| 2016 | -105.24 Million USD | 10.31% |
| 2015 | -125.16 Million USD | -458.4% |
| 2014 | 97.48 Million USD | -116.82% |
| 2013 | 115.38 Million USD | 2412.39% |
| 2012 | 158.18 Million USD | 116.13% |
| 2011 | -38.39 Million USD | -11.82% |
| 2010 | -34.54 Million USD | -124.5% |
| 2009 | -13.7 Million USD | 211.61% |
| 2008 | 152.53 Million USD | -696.79% |
| 2007 | 201.33 Million USD | -7.03% |
| 2006 | 23.03 Million USD | 161.61% |
| 2005 | 24.54 Million USD | 51.14% |
| 2004 | -51.23 Million USD | 38.44% |
| 2003 | -86.19 Million USD | -163.04% |
| 2002 | -66.4 Million USD | -133.57% |
| 2001 | -51.87 Million USD | 68.04% |
| 2000 | -22.2 Million USD | -550.12% |
| 1999 | -69.5 Million USD | -94.54% |
| 1998 | -23.8 Million USD | 63.0% |
| 1997 | -6.16 Million USD | -17.86% |
| 1996 | -14.85 Million USD | -24.75% |
| 1995 | -9.6 Million USD | 41.95% |
| 1994 | -9.6 Million USD | 59.63% |
| 1993 | -15.8 Million USD | -482.43% |
| 1992 | -40.8 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 51.36 Million USD | -29.92% |
| 2024 Q3 | 123.2 Million USD | 5.72% |
| 2024 Q2 | 116.54 Million USD | 126.89% |
| 2023 Q4 | 72.85 Million USD | 16.82% |
| 2023 Q1 | -33.76 Million USD | -335.48% |
| 2023 Q2 | 254.33 Million USD | 853.21% |
| 2023 FY | - USD | 606.22% |
| 2023 Q3 | 62.36 Million USD | -75.48% |
| 2022 FY | - USD | -936.97% |
| 2022 Q1 | -4.38 Million USD | -133.73% |
| 2022 Q2 | -12.36 Million USD | -181.93% |
| 2022 Q3 | -40.66 Million USD | -229.01% |
| 2022 Q4 | -7.75 Million USD | 80.93% |
| 2021 Q1 | 3.68 Million USD | 121.43% |
| 2021 FY | - USD | 121.94% |
| 2021 Q2 | 23.29 Million USD | 532.75% |
| 2021 Q3 | -9.28 Million USD | -139.87% |
| 2021 Q4 | 12.99 Million USD | 239.94% |
| 2020 Q1 | -14.66 Million USD | -176.31% |
| 2020 Q2 | -9.19 Million USD | 37.26% |
| 2020 Q3 | 20.65 Million USD | 324.57% |
| 2020 Q4 | -17.17 Million USD | -183.17% |
| 2020 FY | - USD | 51.01% |
| 2019 Q3 | -31.43 Million USD | -200.72% |
| 2019 Q2 | -10.45 Million USD | 83.72% |
| 2019 FY | - USD | -299.43% |
| 2019 Q1 | -64.2 Million USD | -314.08% |
| 2019 Q4 | 19.21 Million USD | 161.12% |
| 2018 Q3 | -8.42 Million USD | -135.01% |
| 2018 Q1 | -43.54 Million USD | -282.03% |
| 2018 FY | - USD | 70.53% |
| 2018 Q4 | 29.98 Million USD | 456.16% |
| 2018 Q2 | 24.05 Million USD | 155.23% |
| 2017 Q4 | 23.92 Million USD | 212.7% |
| 2017 FY | - USD | 37.99% |
| 2017 Q1 | -47.66 Million USD | -435.9% |
| 2017 Q2 | -18.95 Million USD | 60.24% |
| 2017 Q3 | -21.22 Million USD | -12.0% |
| 2016 Q4 | -8.89 Million USD | 76.06% |
| 2016 Q3 | -37.14 Million USD | -58.03% |
| 2016 FY | - USD | 10.31% |
| 2016 Q2 | -23.5 Million USD | 55.58% |
| 2016 Q1 | -52.92 Million USD | -1.04% |
| 2015 Q1 | -4.37 Million USD | -2515.47% |
| 2015 FY | - USD | -458.4% |
| 2015 Q4 | -52.37 Million USD | 5.14% |
| 2015 Q3 | -55.21 Million USD | -80.91% |
| 2015 Q2 | -30.52 Million USD | -598.08% |
| 2014 FY | - USD | -116.82% |
| 2014 Q1 | 5.32 Million USD | -81.78% |
| 2014 Q2 | -6.89 Million USD | -229.58% |
| 2014 Q4 | 181 Thousand USD | 102.3% |
| 2014 Q3 | -7.88 Million USD | -14.29% |
| 2013 Q3 | 19.62 Million USD | -47.32% |
| 2013 Q1 | 37.66 Million USD | 4.86% |
| 2013 FY | - USD | 2412.39% |
| 2013 Q4 | 29.2 Million USD | 48.86% |
| 2013 Q2 | 37.24 Million USD | -1.1% |
| 2012 FY | - USD | 116.13% |
| 2012 Q4 | 35.91 Million USD | 46.89% |
| 2012 Q3 | 24.45 Million USD | -42.98% |
| 2012 Q2 | 42.87 Million USD | 374.0% |
| 2012 Q1 | 9.04 Million USD | -44.36% |
| 2011 Q3 | -6.91 Million USD | 39.76% |
| 2011 Q4 | 16.25 Million USD | 335.23% |
| 2011 FY | - USD | -11.82% |
| 2011 Q2 | -11.47 Million USD | -8.16% |
| 2011 Q1 | -10.6 Million USD | -16.42% |
| 2010 FY | - USD | -124.5% |
| 2010 Q1 | -12.83 Million USD | -3217.05% |
| 2010 Q4 | -9.11 Million USD | -106.97% |
| 2010 Q3 | -4.4 Million USD | 64.02% |
| 2010 Q2 | -12.23 Million USD | 4.68% |
| 2009 Q2 | 1.48 Million USD | 356.03% |
| 2009 Q1 | -580 Thousand USD | -100.5% |
| 2009 FY | - USD | 211.61% |
| 2009 Q4 | -387 Thousand USD | 75.84% |
| 2009 Q3 | -1.6 Million USD | -207.88% |
| 2008 Q1 | 10.72 Million USD | 106.19% |
| 2008 Q3 | 6.9 Million USD | -79.81% |
| 2008 Q4 | 116.12 Million USD | 1582.79% |
| 2008 FY | - USD | -696.79% |
| 2008 Q2 | 34.17 Million USD | 218.62% |
| 2007 Q4 | -173.34 Million USD | -2113.05% |
| 2007 Q2 | 13.67 Million USD | 69.37% |
| 2007 Q1 | 8.07 Million USD | 31.68% |
| 2007 FY | - USD | -7.03% |
| 2007 Q3 | 8.61 Million USD | -37.04% |
| 2006 Q4 | 6.13 Million USD | -17.78% |
| 2006 Q3 | 7.45 Million USD | 304.06% |
| 2006 Q2 | 1.84 Million USD | -81.93% |
| 2006 Q1 | 10.21 Million USD | 60.08% |
| 2006 FY | - USD | 161.61% |
| 2005 FY | - USD | 51.14% |
| 2005 Q4 | 6.38 Million USD | 61.02% |
| 2005 Q1 | -11.8 Million USD | -114.97% |
| 2005 Q2 | -7.72 Million USD | 34.51% |
| 2005 Q3 | 3.96 Million USD | 151.29% |
| 2004 Q4 | -5.48 Million USD | 55.77% |
| 2004 Q1 | -25.82 Million USD | -47.64% |
| 2004 FY | - USD | 38.44% |
| 2004 Q2 | -11.34 Million USD | 56.06% |
| 2004 Q3 | -12.41 Million USD | -9.38% |
| 2003 Q1 | -15.94 Million USD | 87.26% |
| 2003 Q3 | -23.57 Million USD | -13.6% |
| 2003 Q4 | -17.58 Million USD | 26.44% |
| 2003 FY | - USD | -163.04% |
| 2003 Q2 | -23.28 Million USD | -88.47% |
| 2002 FY | - USD | -133.57% |
| 2002 Q4 | -8.61 Million USD | -707.53% |
| 2002 Q1 | -16.82 Million USD | -10.43% |
| 2002 Q2 | -18 Million USD | -2.54% |
| 2002 Q3 | -23.83 Million USD | 183.19% |
| 2001 FY | - USD | 68.04% |
| 2001 Q3 | -11.54 Million USD | -40.09% |
| 2001 Q1 | -12.36 Million USD | -44.94% |
| 2001 Q2 | -8.24 Million USD | 33.32% |
| 2001 Q4 | -15.23 Million USD | -31.93% |
| 2000 Q2 | 8.19 Million USD | 121.44% |
| 2000 FY | - USD | -550.12% |
| 2000 Q4 | -8.53 Million USD | 10.26% |
| 2000 Q1 | -38.2 Million USD | -548.01% |
| 2000 Q3 | -9.5 Million USD | -216.04% |
| 1999 FY | - USD | -94.54% |
| 1999 Q3 | -14.48 Million USD | -44.46% |
| 1999 Q2 | -8.25 Million USD | 53.04% |
| 1999 Q1 | -12.2 Million USD | -2836.73% |
| 1999 Q4 | -17.4 Million USD | 28.81% |
| 1998 Q1 | -974.44 Thousand USD | 49.76% |
| 1998 FY | - USD | 63.0% |
| 1998 Q4 | -1.19 Million USD | 59.92% |
| 1998 Q3 | -2.26 Million USD | -134.93% |
| 1998 Q2 | -851.8 Thousand USD | 404.69% |
| 1997 Q1 | -3.78 Million USD | -18.61% |
| 1997 FY | - USD | -17.86% |
| 1997 Q4 | -1.93 Million USD | -967.13% |
| 1997 Q3 | 223.66 Thousand USD | 107.97% |
| 1997 Q2 | -2.8 Million USD | 25.98% |
| 1996 Q3 | -3.87 Million USD | 2.75% |
| 1996 Q4 | -3.19 Million USD | 17.62% |
| 1996 Q2 | -3.98 Million USD | 0.3% |
| 1996 Q1 | -4.3 Million USD | -25.0% |
| 1996 FY | - USD | -24.75% |
| 1995 Q2 | -1.71 Million USD | -71.43% |
| 1995 Q1 | -2 Million USD | 26.32% |
| 1995 Q4 | -1.96 Million USD | -6.67% |
| 1995 FY | - USD | 41.95% |
| 1995 Q3 | -2.16 Million USD | -25.0% |
| 1994 FY | - USD | 59.63% |
| 1994 Q4 | -1.5 Million USD | 36.67% |
| 1994 Q3 | -2.7 Million USD | 18.92% |
| 1994 Q2 | -3.3 Million USD | -27.59% |
| 1994 Q1 | -2.6 Million USD | 44.23% |
| 1993 Q4 | -4.8 Million USD | -33.33% |
| 1993 Q1 | -34.8 Million USD | -1117.24% |
| 1993 FY | - USD | -482.43% |
| 1993 Q2 | -4.7 Million USD | 85.55% |
| 1993 Q3 | -3.5 Million USD | 23.53% |
| 1992 Q3 | -2.5 Million USD | -55.0% |
| 1992 FY | - USD | 0.0% |
| 1992 Q2 | -1.4 Million USD | 77.78% |
| 1992 Q1 | -9 Million USD | -1385.71% |
| 1992 Q4 | -2.3 Million USD | 6.45% |
| 1991 Q4 | 700 Thousand USD | 141.18% |
| 1991 Q2 | -1.8 Million USD | 0.0% |
| 1991 Q3 | -1.5 Million USD | 10.53% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AbCellera Biologics Inc. | -192.15 Million USD | 357.626% |
| Agenus Inc. | -145.92 Million USD | 439.251% |
| Aptorum Group Limited | -9.59 Million USD | 5257.299% |
| Ardelyx, Inc. | -55.35 Million USD | 994.333% |
| Dyadic International, Inc. | -8.22 Million USD | 6115.367% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | 170219.931% |
| Lantern Pharma Inc. | -15.78 Million USD | 3235.863% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | 2586.135% |
| Novavax, Inc. | -487.39 Million USD | 201.571% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 797.017% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 730.692% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | 2854.335% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | 5066.382% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | 962.816% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 230.287% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 2153.132% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | -93482.042% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 414.927% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 761.699% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 2555.722% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | 2185.734% |
| Clearside Biomedical, Inc. | -23.05 Million USD | 2246.973% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 505.436% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 291.7% |
| AlloVir, Inc. | -190.14 Million USD | 360.352% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 381.803% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 1792.012% |
| Bicycle Therapeutics plc | -183.4 Million USD | 369.929% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 399.266% |
| ChromaDex Corporation | -3.89 Million USD | 12813.123% |
| Chimerix, Inc. | -92.97 Million USD | 632.46% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 1214.054% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 539.911% |
| CRISPR Therapeutics AG | -202.7 Million USD | 344.226% |
| Precision BioSciences, Inc. | -32.04 Million USD | 1645.0% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 387.436% |
| Fortress Biotech, Inc. | -133.64 Million USD | 470.426% |
| Fortress Biotech, Inc. | -133.64 Million USD | 470.426% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 740.07% |
| ImmuCell Corporation | -2.5 Million USD | 19869.72% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 479.578% |
| Immix Biopharma, Inc. | -16.13 Million USD | 3168.046% |
| Incyte Corporation | 919.42 Million USD | 46.157% |
| Innoviva, Inc. | 248.96 Million USD | -98.847% |
| IO Biotech, Inc. | -91.22 Million USD | 642.65% |
| Jaguar Health, Inc. | -33.13 Million USD | 1594.217% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 425.311% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | -386.645% |
| ContextLogic Inc. | -324 Million USD | 252.793% |
| MiMedx Group, Inc. | 40.51 Million USD | -1121.83% |
| MEI Pharma, Inc. | 26.38 Million USD | -1776.607% |
| NextCure, Inc. | -59.03 Million USD | 938.512% |
| Onconetix, Inc. | -36.7 Million USD | 1448.66% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | -22049.843% |
| Opthea Limited | -200.01 Million USD | 347.501% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 18091.445% |
| Vaxcyte, Inc. | -464.88 Million USD | 206.488% |
| PDS Biotechnology Corporation | -40.08 Million USD | 1334.999% |
| Precigen, Inc. | -89.22 Million USD | 654.826% |
| Pharming Group N.V. | 9.87 Million USD | -4912.139% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 411.256% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | 2274.892% |
| PureTech Health plc | -11.62 Million USD | 4357.754% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | 3015.311% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 312.015% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 2153.132% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 666.243% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | 1809.246% |
| Acelyrin, Inc. | -381.52 Million USD | 229.755% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | 3842189.455% |
| Summit Therapeutics Inc. | 1 Million USD | -49355.445% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | 1582.804% |
| Senti Biosciences, Inc. | -61.33 Million USD | 907.11% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 540.812% |
| Elevation Oncology, Inc. | -41.46 Million USD | 1293.838% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | 1701.893% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | 8193.604% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | 154320.872% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | 1625.434% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | 5996.248% |
| Wave Life Sciences Ltd. | -58.79 Million USD | 942.063% |
| Seer, Inc. | -97.88 Million USD | 605.746% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | 895.937% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 857.361% |
| ESSA Pharma Inc. | -26.45 Million USD | 1971.265% |
| GlycoMimetics, Inc. | -39.12 Million USD | 1365.398% |
| GT Biopharma, Inc. | 5.97 Million USD | -8179.796% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 339.509% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | 7308.052% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -470.254% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 972.272% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | 1066.534% |
| Alzamend Neuro, Inc. | -9.88 Million USD | 5107.118% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 191.688% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | 7291.299% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 1156.398% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 309.215% |
| Aptose Biosciences Inc. | -52.26 Million USD | 1047.136% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 559.47% |
| Soligenix, Inc. | -7.85 Million USD | 6404.068% |
| Century Therapeutics, Inc. | -121.2 Million USD | 508.429% |
| Kura Oncology, Inc. | -164.95 Million USD | 400.112% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 718.054% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | 5008.279% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | 51789.343% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | 11588.721% |
| Autolus Therapeutics plc | -156.77 Million USD | 415.78% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 684.77% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 817.452% |
| Eterna Therapeutics Inc. | -19.93 Million USD | 2583.44% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 361.553% |
| GRI Bio, Inc. | -10.89 Million USD | 4642.567% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 11062.804% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 504.102% |
| IGM Biosciences, Inc. | -253.35 Million USD | 295.395% |
| INmune Bio, Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 576.963% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 1398.209% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 3329.091% |
| Entero Therapeutics, Inc. | -15.74 Million USD | 3244.518% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | 970.875% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 562.218% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 286.111% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 355.26% |
| Verastem, Inc. | -83.16 Million USD | 695.254% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 1078.899% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 412.871% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 533.915% |
| Histogen Inc. | -10.5 Million USD | 4813.406% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | 3566.801% |
| Surrozen, Inc. | -41.13 Million USD | 1303.591% |
| Organovo Holdings, Inc. | -14.8 Million USD | 3443.57% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -15436413.876% |
| Ovid Therapeutics Inc. | -58.71 Million USD | 943.165% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 1065.121% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | 2398.384% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | 6037.26% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 398.103% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | 1105.003% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | 2148.535% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | 3388.261% |
| Apollomics, Inc. | -171.74 Million USD | 388.243% |
| Amarin Corporation plc | -50.9 Million USD | 1072.562% |
| Mesoblast Limited | -61.33 Million USD | 907.176% |
| Turnstone Biologics Corp. | -56.23 Million USD | 980.338% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 445.702% |
| Synaptogenix, Inc. | -8.3 Million USD | 6059.056% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | 3327.388% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | 885.206% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 10431.89% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | -115285.548% |
| Exelixis, Inc. | 196.6 Million USD | -151.803% |
| Better Therapeutics, Inc. | -38.26 Million USD | 1393.84% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 450.083% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 199.967% |
| NLS Pharmaceutics AG | -11.79 Million USD | 4296.876% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | -200149.579% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 1777.791% |
| Gritstone bio, Inc. | -126.86 Million USD | 490.223% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 861.79% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 12476.392% |
| Avid Bioservices, Inc. | -11.48 Million USD | 4411.898% |
| Insmed Incorporated | -654.73 Million USD | 175.61% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | 22104.926% |
| MediWound Ltd. | -4.89 Million USD | 10217.494% |
| OmniAb, Inc. | -49.73 Million USD | 1095.454% |
| Alector, Inc. | -142.89 Million USD | 446.45% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 679.452% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 1049.315% |
| Zai Lab Limited | -366.57 Million USD | 235.048% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 270.332% |
| Aura Biosciences, Inc. | -83.69 Million USD | 691.485% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 319.779% |
| Immunic, Inc. | -99.11 Million USD | 599.484% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 475.977% |
| Veracyte, Inc. | -49.4 Million USD | 1101.941% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | 7108.123% |
| FibroGen, Inc. | -261.4 Million USD | 289.38% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 4543.488% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 7170.787% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | 2744.935% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 65.845% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | 2047.325% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | -1141.035% |
| TG Therapeutics, Inc. | 26.1 Million USD | -1796.739% |
| Galecto, Inc. | -37.51 Million USD | 1419.462% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 1393.738% |
| Fortrea Holdings Inc. | 167.3 Million USD | -195.905% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 468.669% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | 1848.61% |
| XBiotech Inc. | -35.76 Million USD | 1484.133% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 861.79% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 858.696% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 573.935% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 2028.362% |
| Theravance Biopharma, Inc. | -40.86 Million USD | 1311.366% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 195.855% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | 983.685% |
| Vaxxinity, Inc. | -56.05 Thousand USD | 883311.718% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 525.537% |
| Gain Therapeutics, Inc. | -22.16 Million USD | 2333.013% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 310.602% |
| NexImmune, Inc. | -28.16 Million USD | 1857.518% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | 9059.274% |
| Marker Therapeutics, Inc. | -11.79 Million USD | 4298.08% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 89.363% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | 2049.626% |
| Scopus BioPharma Inc. | -11.71 Million USD | 4326.438% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 493.377% |
| Ainos, Inc. | -8.77 Million USD | 5742.807% |
| Pluri Inc. | -20.22 Million USD | 2547.708% |
| Prothena Corporation plc | -190.1 Million USD | 360.404% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 486.16% |
| Celularity Inc. | -183.94 Million USD | 369.127% |
| Rallybio Corporation | -72.37 Million USD | 784.024% |
| Cue Biopharma, Inc. | -46.05 Million USD | 1174.978% |
| MeiraGTx Holdings plc | -57.05 Million USD | 967.715% |
| Omeros Corporation | -163.61 Million USD | 402.579% |
| Humacyte, Inc. | -96.45 Million USD | 613.228% |
| Immunocore Holdings plc | -59.64 Million USD | 929.937% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | 2655.487% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | 2131.804% |
| Blueprint Medicines Corporation | -474.61 Million USD | 204.306% |
| CalciMedica, Inc. | -34.18 Million USD | 1547.977% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 775.982% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 494.471% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 393.883% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 296.144% |
| Pulmatrix, Inc. | -12.64 Million USD | 4014.669% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | 1601.696% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 659.586% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 197.775% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 589.106% |
| Cytokinetics, Incorporated | -456.68 Million USD | 208.401% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 1583.382% |
| Nutriband Inc. | -5.12 Million USD | 9765.571% |
| Protara Therapeutics, Inc. | -43.27 Million USD | 1244.04% |
| Vor Biopharma Inc. | -114.37 Million USD | 532.845% |
| Roivant Sciences Ltd. | -996.51 Million USD | 149.678% |
| Evogene Ltd. | -23.2 Million USD | 2233.464% |
| ProKidney Corp. | -147.66 Million USD | 435.242% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 867.102% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | 323346.642% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 187.547% |
| CorMedix Inc. | -48.88 Million USD | 1112.639% |
| BioLineRx Ltd. | -57.06 Million USD | 967.579% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 542.965% |
| Galectin Therapeutics Inc. | -202 Thousand USD | 245173.762% |
| Atai Life Sciences N.V. | -36.31 Million USD | 1463.358% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 722.57% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 708.819% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 279.689% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 1710.439% |
| MediciNova, Inc. | -9.87 Million USD | 5110.633% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 493.08% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 32451.894% |
| GeoVax Labs, Inc. | -26.66 Million USD | 1956.287% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 320.031% |
| Biomea Fusion, Inc. | -124.62 Million USD | 497.247% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 249.86% |
| Mereo BioPharma Group plc | -26.05 Million USD | 1999.942% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 360.088% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 315.293% |
| Absci Corporation | -95.45 Million USD | 618.609% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 1748.789% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 562.153% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 312.034% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | 2266.042% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 338.192% |
| Allakos Inc. | -189.91 Million USD | 360.669% |
| Imunon, Inc. | -19.87 Million USD | 2590.402% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 556.3% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -357.008% |
| BioAtla, Inc. | -122.24 Million USD | 504.978% |
| NLS Pharmaceutics AG | -11.79 Million USD | 4296.876% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 3240.975% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 264.855% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | 1294.415% |
| XOMA Corporation | -39.36 Million USD | 1357.683% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 598.77% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 520.781% |
| aTyr Pharma, Inc. | -52.17 Million USD | 1048.77% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 690.645% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 433.073% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 311.05% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | 3725.936% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | 6255.565% |
| Akari Therapeutics, Plc | -16.8 Million USD | 3046.369% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -262238.77% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | -9.537% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 7848.913% |
| UroGen Pharma Ltd. | -63.83 Million USD | 875.562% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 828.924% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 6916.029% |
| Orgenesis Inc. | -60.71 Million USD | 915.325% |
| Entera Bio Ltd. | -8.8 Million USD | 5723.001% |
| GH Research PLC | -41.15 Million USD | 1302.948% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | 2039.923% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 702.008% |
| Xencor, Inc. | -125.87 Million USD | 493.289% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | 34802.656% |
| Replimune Group, Inc. | -230.19 Million USD | 315.054% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | 2555.89% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | 4624.301% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 7848.913% |
| Portage Biotech Inc. | -18.19 Million USD | 2820.199% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 32451.894% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 573.351% |
| OncoCyte Corporation | -23.12 Million USD | 2240.938% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 4480.824% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 4420.991% |
| Purple Biotech Ltd. | -22.22 Million USD | 2327.442% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | 7823.073% |
| scPharmaceuticals Inc. | -46.06 Million USD | 1174.768% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | 2879.662% |
| HilleVax, Inc. | -132.46 Million USD | 473.718% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | 4755.779% |
| Tharimmune, Inc. | -9.3 Million USD | 5421.626% |
| Genprex, Inc. | -31.06 Million USD | 1693.818% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 363.99% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | 1678.902% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | 64896.99% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | -327955.585% |
| OKYO Pharma Limited | -15.74 Thousand USD | 3144092.679% |
| Savara Inc. | -59.13 Million USD | 937.179% |
| Curis, Inc. | -45.13 Million USD | 1196.721% |
| Daré Bioscience, Inc. | -30.7 Million USD | 1712.458% |
| Carmell Therapeutics Corporation | -15.19 Million USD | 3358.799% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | 7009.267% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | 1951.758% |
| BeiGene, Ltd. | -1.12 Billion USD | 144.02% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 3136.887% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 214.972% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 647.984% |
| Erasca, Inc. | -121.31 Million USD | 508.086% |
| bluebird bio, Inc. | -167.16 Million USD | 396.151% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 11104.131% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | -59.547% |
| DBV Technologies S.A. | -85.98 Million USD | 675.759% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 11104.131% |
| Moderna, Inc. | -3.28 Billion USD | 115.079% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 1261.841% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | 8865.032% |
| Molecular Templates, Inc. | 1.43 Million USD | -34518.811% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | 927.122% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 251.741% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 461.115% |
| Spruce Biosciences, Inc. | -47.36 Million USD | 1145.157% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 456.063% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 340.478% |
| MacroGenics, Inc. | 2.01 Million USD | -24443.827% |
| RenovoRx, Inc. | -11.39 Million USD | 4446.348% |
| Adicet Bio, Inc. | -136.53 Million USD | 462.58% |
| Prime Medicine, Inc. | -193.75 Million USD | 355.497% |
| Aditxt, Inc. | -25.45 Million USD | 2044.574% |
| Adagene Inc. | -14.95 Million USD | 3411.191% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 6872.125% |
| Quantum-Si incorporated | -91.8 Million USD | 639.246% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 30.511% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | -291.482% |
| SciSparc Ltd. | -5.28 Million USD | 9472.378% |
| Vericel Corporation | 2.86 Million USD | -17185.23% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 520065.759% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | 2382.233% |
| Generation Bio Co. | -133.3 Million USD | 471.38% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 696.229% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 675.484% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 317.667% |
| Invivyd, Inc. | -196.61 Million USD | 351.786% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 232.312% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | 5437.572% |
| Spero Therapeutics, Inc. | 27.15 Million USD | -1723.116% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 4913.311% |
| 2seventy bio, Inc. | -206.41 Million USD | 339.828% |
| ADMA Biologics, Inc. | 5.12 Million USD | -9568.926% |
| Clene Inc. | -43.24 Million USD | 1244.86% |
| Capricor Therapeutics, Inc. | -23 Million USD | 2251.547% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | 1121.204% |
| GeoVax Labs, Inc. | -26.66 Million USD | 1956.287% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 265.255% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | 1447.829% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | -2000.068% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | -9981.941% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 1624.072% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 412.523% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 172.343% |
| Evaxion Biotech A/S | -21.4 Million USD | 2412.989% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 845.387% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 327.432% |
| Trevena, Inc. | -35.28 Million USD | 1502.882% |
| Surrozen, Inc. | -41.13 Million USD | 1303.591% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 721.983% |
| Cingulate Inc. | -22.95 Million USD | 2256.885% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | 6735.156% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 1427.814% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | 6117.83% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 584.08% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 829.87% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | 948.093% |
| Clearmind Medicine Inc. | -8.71 Million USD | 5783.253% |
| Kronos Bio, Inc. | -121.83 Million USD | 506.344% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 765.908% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 20377.143% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 590.989% |
| Statera Biopharma, Inc. | 38.93 Million USD | -1171.477% |
| ImmunityBio, Inc. | -436.18 Million USD | 213.496% |
| Korro Bio, Inc. | -80.9 Million USD | 711.897% |
| Kineta, Inc. | -15.71 Million USD | 3250.369% |
| BioVie Inc. | -31.95 Million USD | 1649.439% |
| Codexis, Inc. | -49.28 Million USD | 1104.503% |
| Celularity Inc. | -183.94 Million USD | 369.127% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 323.488% |
| Celcuity Inc. | -58.3 Million USD | 948.996% |
| Virax Biolabs Group Limited | -6.6 Million USD | 7590.365% |
| Cibus, Inc. | -314.58 Million USD | 257.366% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 1567.551% |
| IN8bio, Inc. | -28.5 Million USD | 1836.77% |
| Kodiak Sciences Inc. | -259.02 Million USD | 291.122% |
| Annexon, Inc. | -141.57 Million USD | 449.673% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 539.657% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 871.152% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | 1870.878% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 315.229% |
| Eyenovia, Inc. | -24.1 Million USD | 2153.631% |
| Puma Biotechnology, Inc. | 44.78 Million USD | -1005.415% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 152892.901% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 770.762% |
| Arcellx, Inc. | -64.14 Million USD | 871.766% |
| Cardiff Oncology, Inc. | -45.01 Million USD | 1199.767% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 500.927% |
| Regulus Therapeutics Inc. | -30.88 Million USD | 1703.034% |
| Moolec Science SA | -52.07 Million USD | 1050.636% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | 1059.286% |
| Geron Corporation | -174.78 Million USD | 383.238% |
| LAVA Therapeutics N.V. | -40.41 Million USD | 1324.853% |
| Royalty Pharma plc | 1.88 Billion USD | 73.769% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 513.945% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 5409.261% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | 2486.842% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 398.079% |
| Humacyte, Inc. | -96.45 Million USD | 613.228% |
| Structure Therapeutics Inc. | -102.45 Million USD | 583.168% |
| 89bio, Inc. | -134.46 Million USD | 468.167% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 727.637% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | -12117.399% |
| Genelux Corporation | -24.16 Million USD | 2148.62% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | 1564.642% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 402.849% |
| Notable Labs, Ltd. | -14.4 Million USD | 3537.84% |
| Liquidia Corporation | -70.05 Million USD | 806.698% |
| Mustang Bio, Inc. | -48.06 Million USD | 1130.0% |
| Immunovant, Inc. | -269.97 Million USD | 283.366% |
| Quantum-Si incorporated | -91.8 Million USD | 639.246% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 797.39% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | 2663.958% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 585.285% |
| Acasti Pharma Inc. | -11.3 Million USD | 4480.577% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | 2324.615% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 3329.091% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 335.163% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | 11692.722% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 3217.437% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | 1820.354% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | 1436.886% |
| PepGen Inc. | -83.58 Million USD | 692.291% |
| Moleculin Biotech, Inc. | -29.5 Million USD | 1777.905% |
| United Therapeutics Corporation | 1.38 Billion USD | 64.303% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 2262.069% |
| Solid Biosciences Inc. | -93.43 Million USD | 629.838% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | 10474.61% |
| Immuneering Corporation | -58.06 Million USD | 952.639% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -15436413.876% |
| Silo Pharma, Inc. | -3.62 Million USD | 13751.952% |
| Belite Bio, Inc | -31.52 Million USD | 1670.139% |
| XOMA Corporation | -39.36 Million USD | 1357.683% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 833.982% |
| Bionomics Limited | -9.83 Million USD | 5132.523% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 689.449% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 1530.529% |
| uniQure N.V. | -253.1 Million USD | 295.594% |
| Cassava Sciences, Inc. | -95.68 Million USD | 617.363% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 6872.125% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 482.265% |
| Forte Biosciences, Inc. | -32.47 Million USD | 1624.306% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | 6249.316% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | 1854.311% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 152892.901% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 4543.488% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | 3213.32% |
| Altimmune, Inc. | -87.93 Million USD | 662.972% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 637.635% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 1530.529% |
| Compugen Ltd. | -12.51 Million USD | 4055.329% |
| Peak Bio, Inc. | -1356.23 USD | 36501947.032% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | 1118.661% |
| Benitec Biopharma Inc. | -22.49 Million USD | 2301.196% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 304.31% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | 1834.397% |
| Zura Bio Limited | -60.56 Million USD | 917.412% |
| PolyPid Ltd. | -20.26 Million USD | 2543.118% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | 3270.749% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | 1834.397% |
| Instil Bio, Inc. | -146.12 Million USD | 438.792% |
| argenx SE | -216.02 Million USD | 329.165% |
| Immunome, Inc. | -28.27 Million USD | 1851.084% |
| Compass Therapeutics, Inc. | -48.47 Million USD | 1121.288% |
| Verona Pharma plc | -52.46 Million USD | 1043.533% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 622.358% |
| Shattuck Labs, Inc. | -87.61 Million USD | 665.028% |
| CervoMed Inc. | -2.17 Million USD | 22893.634% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 504.968% |
| Plus Therapeutics, Inc. | -12.69 Million USD | 4000.173% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 1127.627% |
| Moolec Science SA | -52.07 Million USD | 1050.636% |
| Enveric Biosciences, Inc. | -17.13 Million USD | 2988.27% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 479.665% |
| AnaptysBio, Inc. | -143.16 Million USD | 445.792% |
| Design Therapeutics, Inc. | -66.32 Million USD | 846.399% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 711.27% |
| NeurAxis, Inc. | -6.66 Million USD | 7528.155% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | 1411.388% |
| Lumos Pharma, Inc. | -36.57 Million USD | 1453.702% |
| Achilles Therapeutics plc | -70.44 Million USD | 802.775% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 622.358% |
| 180 Life Sciences Corp. | -22.13 Million USD | 2336.597% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | -8392.503% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 20377.143% |
| Nutriband Inc. | -5.12 Million USD | 9765.571% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 551.078% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | 993.074% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | 1079.325% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 858.382% |
| MoonLake Immunotherapeutics | -54.1 Million USD | 1014.895% |
| Palisade Bio, Inc. | -12.28 Million USD | 4131.015% |
| Tourmaline Bio, Inc. | -45.37 Million USD | 1190.993% |
| Beam Therapeutics Inc. | -156.47 Million USD | 416.38% |
| Neurogene Inc. | -52.28 Million USD | 1046.81% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 462.7% |
| AEON Biopharma, Inc. | -48.36 Million USD | 1123.653% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 632.208% |
| Sesen Bio, Inc. | -50.84 Million USD | 1073.739% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 704.219% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | 4108.486% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 215.819% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 570.592% |
| Athira Pharma, Inc. | -116.7 Million USD | 524.196% |
| Vaccinex, Inc. | -19.74 Million USD | 2606.831% |
| HCW Biologics Inc. | -23.57 Million USD | 2199.796% |
| XOMA Corporation | -39.36 Million USD | 1357.683% |
| Nektar Therapeutics | -243.1 Million USD | 303.634% |
| Arvinas, Inc. | -394.8 Million USD | 225.392% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -262238.77% |
| Merus N.V. | -149.2 Million USD | 431.787% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 629.521% |
| Quince Therapeutics, Inc. | -31.26 Million USD | 1683.65% |
| Rezolute, Inc. | -68.42 Million USD | 823.513% |
| Clene Inc. | -43.24 Million USD | 1244.86% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 3309.979% |
| BeyondSpring Inc. | -21.54 Million USD | 2398.278% |
| Synlogic, Inc. | -55.16 Million USD | 997.462% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | 4197.07% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | 4751.842% |
| Peak Bio, Inc. | -1356.23 USD | 36501947.032% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | 1624.87% |
| Krystal Biotech, Inc. | 17.9 Million USD | -2665.019% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 518.035% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 245.029% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | 10846.908% |
| MannKind Corporation | 15.12 Million USD | -3172.186% |
| Ikena Oncology, Inc. | -74.39 Million USD | 765.415% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | 4031.144% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | -2335.426% |
| Gossamer Bio, Inc. | -172.15 Million USD | 387.565% |
| CohBar, Inc. | -12.06 Million USD | 4202.925% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | 2040.684% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 1748.789% |
| Legend Biotech Corporation | -477.87 Million USD | 203.594% |
| Mural Oncology plc | -192.72 Million USD | 356.875% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 534.048% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 3166.217% |
| Disc Medicine, Inc. | -91.02 Million USD | 643.86% |
| Champions Oncology, Inc. | -5.05 Million USD | 9895.192% |
| REGENXBIO Inc. | -239.46 Million USD | 306.732% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 4718.776% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 987.885% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | 1376.944% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 538.85% |
| Vaxart, Inc. | -74.72 Million USD | 762.512% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | 1506.058% |
| Cellectis S.A. | -98.09 Million USD | 604.663% |
| Longeveron Inc. | -20.06 Million USD | 2567.841% |
| Repare Therapeutics Inc. | -114.27 Million USD | 533.216% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 212.717% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 761.724% |
| Revolution Medicines, Inc. | -430.58 Million USD | 214.972% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | 7971.665% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | 1707.876% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 763.694% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | -9996.859% |
| Anixa Biosciences, Inc. | -10.96 Million USD | 4614.811% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 89.25% |
| Denali Therapeutics Inc. | -179.97 Million USD | 375.068% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 520065.759% |
| Veru Inc. | -89.97 Million USD | 650.204% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | 1941.837% |
| Cingulate Inc. | -22.95 Million USD | 2256.885% |
| Passage Bio, Inc. | -98.34 Million USD | 603.4% |
| Context Therapeutics Inc. | -25.06 Million USD | 2075.41% |
| Exicure, Inc. | -15.53 Million USD | 3285.849% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 340.24% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | 1438.839% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | 8402.575% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 393.86% |
| Nuvalent, Inc. | -149.49 Million USD | 431.154% |
| ABVC BioPharma, Inc. | -8.13 Million USD | 6187.355% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 676.349% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | 1740.43% |
| OmniAb, Inc. | -49.73 Million USD | 1095.454% |
| Anew Medical, Inc. | -1.3 Million USD | 38156.102% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | 4103.955% |
| Lipocine Inc. | -16.32 Million USD | 3132.893% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 842.536% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 766.257% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 1398.209% |
| G1 Therapeutics, Inc. | -39.01 Million USD | 1368.901% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | 2331.659% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 190.823% |
| Ocugen, Inc. | -64.82 Million USD | 863.646% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 634.783% |
| Q32 Bio Inc. | -86.5 Million USD | 672.298% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | 3024.612% |
| Alumis Inc. Common Stock | -156.89 Million USD | 415.539% |
| Equillium, Inc. | -12.13 Million USD | 4178.506% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | 946.643% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 6363.788% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 2724.727% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 1160.244% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 565.512% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 2867.71% |
| Dominari Holdings Inc. | -22.44 Million USD | 2306.101% |
| Edesa Biotech, Inc. | -8.19 Million USD | 6144.45% |
| vTv Therapeutics Inc. | -25.41 Million USD | 2048.091% |
| Bio-Techne Corporation | 326.66 Million USD | -51.547% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 228.63% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | -128.777% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 477.589% |
| Candel Therapeutics, Inc. | -37.43 Million USD | 1422.564% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 427.628% |
| Nkarta, Inc. | -120.48 Million USD | 510.894% |
| BioCardia, Inc. | -11.56 Million USD | 4382.431% |
| Iterum Therapeutics plc | -34.58 Million USD | 1531.605% |